Journal article
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States
Clinical infectious diseases, Vol.75(Suppl. 2), pp.S159-S166
06/08/2022
DOI: 10.1093/cid/ciac439
PMCID: PMC9214149
PMID: 35675695
Abstract
Adults in the United States (US) began receiving the viral vector COVID-19 vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use.
In a multicenter case-control analysis of US adults (≥18 years) hospitalized March 11-December 15, 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression.
After excluding patients receiving mRNA vaccines, among 3,979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2.229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% CI: 63%-75%) overall, including 55% (29%-72%) among immunocompromised patients, and 72% (64%-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59%-82%]), 91-180 days (71% [60%-80%]), and 181-274 days (70% [54%-81%]) post-vaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18%-65%) among immunocompetent patients.
The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months post-vaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.
Details
- Title: Subtitle
- Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States
- Creators
- Nathaniel M Lewis - Centers for Disease Control and PreventionWesley H Self - Vanderbilt University Medical CenterManjusha Gaglani - Texas A&M UniversityAdit A Ginde - University of Colorado DenverDavid J Douin - University of Colorado DenverH. Keipp Talbot - Vanderbilt University Medical CenterJonathan D Casey - Vanderbilt University Medical CenterNicholas M Mohr - University of IowaAnne Zepeski - University of IowaShekhar A Ghamande - Baylor Scott & White HealthTresa A McNeal - Baylor Scott & White HealthNathan I Shapiro - Beth Israel Deaconess Medical CenterKevin W Gibbs - Atrium Health Wake Forest BaptistD Clark Files - Atrium Health Wake Forest BaptistDavid N Hager - Johns Hopkins HospitalArber Shehu - Johns Hopkins HospitalMatthew E Prekker - Hennepin County Medical CenterHeidi L Erickson - Hennepin County Medical CenterMichelle N Gong - Albert Einstein College of MedicineAmira Mohamed - Albert Einstein College of MedicineNicholas J Johnson - University of WashingtonVasisht Srinivasan - University of WashingtonJay S Steingrub - Baystate Medical CenterIthan D Peltan - Intermountain Medical CenterAmuel M Brown - Intermountain Medical CenterEmily T Martin - University of MichiganArnold S Monto - University of MichiganAkram Khan - University of MichiganLaurence W Busse - Emory UniversityCaitlin C Ten Lohuis - Emory University School of MedicineBhijit Duggal - Cleveland ClinicJennifer G Wilson - Stanford UniversityAlexandra June Gordon - Stanford UniversityNida Qadir - Ronald Reagan UCLA Medical CenterSteven Y Chang - Ronald Reagan UCLA Medical CenterChristopher Mallow - University of MiamiCarolina Rivas - University of MiamiHilary M Babcock - Washington University in St. LouisJennie H Kwon - Washington University in St. LouisMatthew C Exline - The Ohio State University Wexner Medical CenterAdam S Lauring - University of MichiganNatasha Halasa - Vanderbilt University Medical CenterJames D Chappell - Vanderbilt University Medical CenterCarlos G Grijalva - Vanderbilt University Medical CenterTodd W Rice - Vanderbilt University Medical CenterJillian P Rhoads - Vanderbilt University Medical CenterIan D Jones - Vanderbilt University Medical CenterWilliam B Stubblefield - Vanderbilt University Medical CenterAdrienne Baughman - Vanderbilt University Medical CenterKelsey N Womack - Vanderbilt University Medical CenterChristopher J Lindsell - Vanderbilt University Medical CenterKimberly W Hart - Vanderbilt University Medical CenterYuwei Zhu - Vanderbilt University Medical CenterKatherine Adams - Centers for Disease Control and PreventionManish M Patel - Centers for Disease Control and PreventionMark W Tenforde - Centers for Disease Control and PreventionIVY Network Collaborators
- Resource Type
- Journal article
- Publication Details
- Clinical infectious diseases, Vol.75(Suppl. 2), pp.S159-S166
- DOI
- 10.1093/cid/ciac439
- PMID
- 35675695
- PMCID
- PMC9214149
- NLM abbreviation
- Clin Infect Dis
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- Grant note
- DOI: 10.13039/100000030, name: Centers for Disease Control and Prevention
- Language
- English
- Date published
- 06/08/2022
- Academic Unit
- Epidemiology; Emergency Medicine; Anesthesia; Injury Prevention Research Center
- Record Identifier
- 9984296128302771
Metrics
15 Record Views